OmniAb opened lower at $5.07, compared with its previous close of $5.10. In the last trading session, the stock traded between $4.73 and $5.08. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in OmniAb is now worth
$ 205.06
Giving a profit of
$ 105.06 (105.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 5 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-0.16 (-3.10%)
Day High
$5.08
Day Low
$4.73
Day Open
$5.07
Prev Close
$5.10
Volume
12,19,790
1W Return
-4.50%
1M Return
3.50%
3M Return
46.00%
6M Return
195.93%
1Y Return
206.96%
Fundamentals
Market Cap ($ Mn)
721
PE Ratio
-
PB Ratio
2.50
PEG Ratio
-
ROE
-23.68%
ROCE
-23.46%
EPS (TTM)
$-0.11
Investment Returns
1 Week
-4.50%
1 Month
3.50%
3 Months
46.00%
6 Months
195.93%
9 Months
190.71%
Financials
Quarterly
All values in $ Mn
3.9
Jun 25
2.2
Sep 25
8.4
Dec 25
14.4
Mar 26
13.4
Jun 26
4.0
Sep 26
Updates
15Oct
OmniAb Q3FY26 Results: Earnings call set for October 30
OmniAb will report Q3FY26 results on October 30, 2026. Conference call scheduled for 8:00 a.m. Eastern time. Platform uses engineered transgenic animals and AI screening. Business model includes upfront fees, milestones, and royalties.
29 days ago
18Aug
OmniAb signs Eli Lilly deal, raises 2026 cash outlook to $53 million
OmniAb Inc. has entered a global collaboration with Eli Lilly for an ion channel program, securing potential milestones up to $370 million. This deal drives an upward revision in 2026 cash guidance to $49-53 million. The announcement follows a Q1 revenue surge to $14.4 million from $4.2 million year-ago, supported by a portfolio of 409 active programs.
2mo ago
17Aug
OmniAb raises 2026 cash guidance to $49-$53 million range
OmniAb, Inc. (NASDAQ: OABI) has raised its 2026 financial guidance, projecting a year-end cash position of $49 million to $53 million, up from the previous range of $37 million to $41 million. The increase is attributed to recent business development and licensing deals that have enhanced the company's liquidity profile. CEO Matt Foehr noted that these partnerships position the firm for accelerated growth.
2mo ago
7Aug
OmniAb raises FY26 sales guidance to $32.000M-$36.000M
OmniAb boosts FY2026 sales guidance to $32.000M-$36.000M, exceeding the $30.807M estimate. The revision reflects strong commercial performance and increased confidence in its immuno-oncology pipeline's revenue generation capabilities for the coming year.
3mo ago
16Jul
OmniAb to report Q2 2026 results on August 6
OmniAb will report financial results for the three and six months ended June 30, 2026, after market close on August 6. A conference call will follow at 4:30 p.m. ET to discuss the results and business updates.
